The US Federal Drug Administration’s equivocal verdict on Sanofi-Aventis’s potential blockbuster drug Acomplia is a blow. FDA’s reservations are announced on 17 February. And if the prove relatively minor, Sanofi faces extra short-term uncertainty about a key new product over which management has proved too optimistic.
It is at a delicate time, Sanofi is counting on Acomplia. In the second half of last year, Allegra and Amaryl — two of its bestsellers faced generic competition for the first time. Their sales fell sharply.
Via: The Business Online
FDA's Reservations on Sanofi Obesity Pill Effect Shares
Add Your Comment
Fresh Comments
on Obese children may suffer... liked this story...when cardiac accidents occur we feign a lot of surprise...this article...
on So, the diet plan doesn't... How much can you control yourself from not having your favorite food, the best way is eat...
on So, the diet plan doesn't... I think yoga can be an effective way to battle out that bulge! It is long-lasting and...
on Surgery for an Attractive... being obese really is a great trouble. moore than physical stress you get more humiliated...
on Land of sushi aims for a... Good that they are trying to slim down. I always used to wonder what the sumo wrestlers...